Global Acute Myeloid Leukemia Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Acute Myeloid Leukemia Therapeutics Market Growth (Status and Outlook) 2023-2029

Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years.

LPI (LP Information)' newest research report, the “Acute Myeloid Leukemia Therapeutics Industry Forecast” looks at past sales and reviews total world Acute Myeloid Leukemia Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Acute Myeloid Leukemia Therapeutics sales for 2023 through 2029. With Acute Myeloid Leukemia Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acute Myeloid Leukemia Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Acute Myeloid Leukemia Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Acute Myeloid Leukemia Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Acute Myeloid Leukemia Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acute Myeloid Leukemia Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acute Myeloid Leukemia Therapeutics.

The global Acute Myeloid Leukemia Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Geographically, acute myeloid leukemia therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, North America held substantial share of the acute myeloid leukemia therapeutics market owing to prominent growth factors including rising incidences of acute myeloid leukemia and increasing geriatric population. Furthermore, advanced healthcare infrastructure, rising need of targeted therapies, huge investment in the development of pipeline drugs, and awareness amongst the population base induced market growth in this region. Asia Pacific is expected to be the fastest growing region over the forecast period owing to growth factors such as rising investments, rising disposable incomes, increasing cancer awareness, and improving healthcare infrastructure. Additionally, increasing inclination towards therapies such as targeted therapies resulting in low collateral damage and stronger efficacy is also anticipated to propel the demand for the acute myeloid leukemia therapeutics market in this region.

This report presents a comprehensive overview, market shares, and growth opportunities of Acute Myeloid Leukemia Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Pipeline Drugs
Chemotherapy Drugs
Chemotherapy Regimens

Segmentation by application
Hospitals
Clinics
Home Care

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ambit Biosciences Corporation
Genzyme Corporation Celgene Corporation
Clavis Pharma ASA
Sunesis Pharmaceuticals
Cephalon
Bristol-Myers Squibb
Novartis International AG
GlaxoSmithKline

Please note: The report will take approximately 2 business days to prepare and deliver.